铁转运蛋白1作为一种新型肿瘤标志物可独立预测肺腺癌患者的生存率。
Sideroflexin1 as a novel tumor marker independently predicts survival in lung adenocarcinoma.
作者信息
Chen Qijiu, Wang Rong, Zhang Jianyong, Zhou Liang
机构信息
Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Department of Gastrointestinal Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
出版信息
Transl Cancer Res. 2019 Aug;8(4):1170-1178. doi: 10.21037/tcr.2019.06.34.
BACKGROUND
Targeted therapy for lung cancers is based on prognostic genes and needs more investigation. No study has yet evaluated the effects of Sideroflexin1 (SFXN1) on lung cancer.
METHODS
Data were analyzed from large patient cohorts in the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO).
RESULTS
The mRNA and protein expression of SFXN1 is apparently upregulated in lung adenocarcinoma (LUAD) tissues. Among LUAD patients, upregulated SFXN1 mRNA expression can independently predict unfavorable overall survival (OS, P=0.006) and recurrence-free survival (RFS; P=0.003). In addition, detection data from DNA copy number alterations (CNAs) showed that 164 (32.03%) of the 512 cases had copy number loss (-2 and -1), while 121 (23.63%) of the cases had copy number amplification (+1 and +2). We also found a weak negative correlation between the methylation status of one CpG site (chr5: 174, 944, 791-174, 944, 793) and SFXN1 expression (P<0.0001).
CONCLUSIONS
Upregulated SFXN1 mRNA expression can be a prognostic biomarker of unfavorable OS and RFS in patients with LUAD.
背景
肺癌的靶向治疗基于预后基因，需要更多研究。尚无研究评估过铁离子翻转蛋白1（SFXN1）对肺癌的影响。
方法
对癌症基因组图谱（TCGA）和基因表达综合数据库（GEO）中的大型患者队列数据进行分析。
结果
SFXN1的mRNA和蛋白表达在肺腺癌（LUAD）组织中明显上调。在LUAD患者中，SFXN1 mRNA表达上调可独立预测不良总生存期（OS，P = 0.006）和无复发生存期（RFS；P = 0.003）。此外，DNA拷贝数改变（CNA）检测数据显示，512例病例中有164例（32.03%）存在拷贝数缺失（-2和-1），而121例（23.63%）存在拷贝数扩增（+1和+2）。我们还发现一个CpG位点（chr5: 174,944,791 - 174,944,793）的甲基化状态与SFXN1表达之间存在弱负相关（P < 0.0001）。
结论
SFXN1 mRNA表达上调可能是LUAD患者不良OS和RFS的预后生物标志物。
Zotero 插件